Lipoic acid offers no improvements in walking speed or other outcomes in patients with progressive multiple sclerosis ...
An American neurologist and an Italian epidemiologist whose work revolutionized the treatment of multiple sclerosis have won ...
Dr. Parisa Khosravi knows exactly what her patients are going through and the shock they might experience when she delivers the diagnosis. As a neuroimmunologist at Central Texas Neurology Consultants ...
—Data from this real-world study revealed that patients with MS being treated with DMTs had a disproportionally higher number of cases of herpes zoster compared with patients treated with other ...
Zacks Investment Research on MSN
FDA issues CRL to SNY's regulatory filing for multiple sclerosis drug
Sanofi SNY announced that the FDA has issued a complete response letter (CRL) to its new drug application (NDA), seeking ...
MS involves both inflammation and neurodegeneration from the outset, not just one after the other. B-cells, a type of immune cell, are now understood to be critical drivers of the disease, a major ...
Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the disease and yet another regulatory setback in another.
Multiple sclerosis (MS) is a chronic autoimmune disease characterized by the disruption of nerve signals and various ...
Sanofi provides update on tolebrutinib in primary progressive multiple sclerosisPERSEUS phase 3 study in primary progressive multiple sclerosis ...
Brazilian researchers, in partnership with French institutions, have developed a tool that can predict how patients will respond to natalizumab, one of the most commonly used drugs for treating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback